Cytosine arabinoside and amphotericin B-induced parkinsonism.
Kulkantrakorn
K
K
Selhorst
J B
JB
Petruska
P J
PJ
D000666:Amphotericin B / Q000009:adverse effects* / Q000627:therapeutic use; D002230:Carbidopa / Q000627:therapeutic use; D003561:Cytarabine / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy*; D007980:Levodopa / Q000627:therapeutic use; D008171:Lung Diseases / Q000188:drug therapy*; D008875:Middle Aged; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000188:drug therapy
D003561:Cytarabine; D007980:Levodopa; D000666:Amphotericin B; D002230:Carbidopa